Document:

PALATIN TECHNOLOGIES, INC. 8-K 

 

EXHIBIT
10.2

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of July 2, 2012, between Palatin
Technologies, Inc., a Delaware corporation (the “Company”), and each of the purchasers signatory hereto (each
such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

 

This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser
(the “Purchase Agreement”).

 

The
Company and each Purchaser hereby agrees as follows:

 

	 	1.		Definitions.

 

Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms
in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Additional
Registration Statement” means the Registration Statement filed pursuant to this Agreement covering the resale of all
Registrable Securities not included in all Registration Statements previously declared effective as a result of a limitation on
the maximum number of shares of Common Stock of the Company permitted to be registered by the staff of the Commission pursuant
to Rule 415.

 

“Advice”
shall have the meaning set forth in Section 7(c).

 

This
“Agreement” shall have the meaning set forth in the preamble of this Agreement.

 

“Company”
shall have the meaning set forth in the preamble of this Agreement.

 

“Demand
Date” shall have the meaning set forth in Section 2.

 

“Demand
Registrable Securities” means as of any date of determination, to the extent not then covered by and salable pursuant
to an effective Registration Statement, (a) all Shares, (b) all shares of Common Stock issuable upon exercise of the Series A
Warrants, without regard to any limitations on exercise of the Series A Warrants, (c) all shares of Common Stock issuable upon
exercise of the Series B Warrants, without regard to any limitations on exercise of the Series B Warrants, and (d) any securities
issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to
the foregoing.

 

    	1

    	 

    
 

“Demand
Registration Statement” means the Registration Statement filed pursuant to this Agreement covering the Demand Registrable
Securities.

 

“Effectiveness
Date” means (i) with respect to the Initial Registration Statement required to be filed hereunder, the 145th calendar
day following the date hereof, (ii) with respect to the Subsequent Registration Statement required to be filed hereunder, the
60th calendar day following the earlier of (x) the date the Company filed the Subsequent Registration Statement and (y) the date
the Company is required to have filed the Subsequent Registration Statement and (iii) with respect to any Additional Registration
Statement required to be filed hereunder, the 90th calendar day following the earlier of (x) the date on which such Registration
Statement is filed and (y) the date on which such Registration Statement is required to have been filed; provided, however,
that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be
reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall
be the fifth (5th) Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise
required above.

 

“Effectiveness
Failure” shall have the meaning set forth in Section 3(m).

 

“Effectiveness
Period” shall have the meaning set forth in Section 2.

 

“Filing
Date” means (i) with respect to the Initial Registration Statement required hereunder, the 60th calendar day following
the date hereof, (ii) with respect to the Subsequent Registration Statement required to be filed hereunder, the 60th calendar
days following the Authorized Shares Increase Date (as defined in the Series B Warrants), (iii) with respect to the Demand Registration
Statement required to be filed hereunder, the 60th calendar days following the Demand Date and (iv) with respect to any Additional
Registration Statement, the later of (x) the date 60 days after the date substantially all of the Registrable Securities registered
under the immediately preceding Registration Statement are sold and (y) the date 6 months from the immediately preceding Registration
Statement has been declared effective.

 

“Filing
Failure” shall have the meaning set forth in Section 3(m).

 

“Financial
Advisors Shares” shall have the meaning set forth in Section 3(t).

 

“Grace
Period” shall have the meaning set forth in Section 3(j).

 

    	2

    	 

    
 

“Holder”
or “Holders” means any Purchaser or Purchasers, and their permitted successors and assigns, that is or are
a holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Initial
Registrable Securities” means, as of any date of determination, (I) (a) all Shares, (b) all shares of Common Stock issuable
upon exercise of the Series A Warrants, without regard to any limitations on exercise of the Series A Warrants and (c) any securities
issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to
the foregoing or (II) such other amount as may be required by the staff of the Commission pursuant
to Rule 415 with any cutback applied pro rata to all Holders and with each Holder entitled to elect the portion of its Shares
and/or Series A Warrant Shares that are to be cut back; provided, however, that any such Initial Registrable
Securities shall cease to be Initial Registrable Securities (and the Company shall not be required to maintain the effectiveness
of any, or file another, Registration Statement hereunder with respect thereto other than as set forth below) as soon as (a) a
Registration Statement with respect to the sale of all Initial Registrable Securities is declared effective by the Commission
under the Securities Act and all such Initial Registrable Securities have been disposed of by the Holders in accordance with such
effective Registration Statement, (b) such Initial Registrable Securities have been previously sold in accordance with Rule 144,
or (c) such securities become eligible for resale without volume or manner-of-sale restrictions pursuant to Rule 144 and without
current public information pursuant to Rule 144(c)(1). For the avoidance of doubt, the fact that Initial Registrable Securities
may at times cease to be Initial Registrable Securities does not prevent them from again becoming Initial Registrable Securities
in the future.

 

“Initial
Registration Statement” means the Registration Statement filed pursuant to this Agreement covering the Initial Registrable
Securities.

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Maintenance
Failure” shall have the meaning set forth in Section 3(m).

 

“Plan
of Distribution” shall have the meaning set forth in Section 2.

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the

 

    	3

    	 

    
 

Registrable
Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective
amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

 

“Purchaser(s)”
shall have the meaning ascribed to such term in the preamble of this Agreement.

 

“Purchase
Agreement” shall have the meaning ascribed to such term in the preamble of this Agreement.

 

“Registrable
Securities” means the Initial Registrable Securities, the Demand Registrable Securities and the Subsequent Registrable
Securities.

 

“Registration
Delay Payment” shall have the meaning set forth in Section 3(m).

 

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2, including (in each
case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any
such registration statement.

 

“Rule
144” shall have the meaning set forth in Section 6.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Selling
Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).

 

“Subsequent
Registrable Securities” means, as of any date of determination, (I) (a) all shares of Common Stock issuable upon exercise
of the Series B Warrants, without regard to any limitations on exercise of the Series B Warrants, (b) to the extent not covered
by an effective Registration Statement, the Initial Registrable Securities and (c) any securities issued or then issuable upon
any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing or (II) such
other amount as may be required by the

 

    	4

    	 

    
 

staff
of the Commission pursuant to Rule 415 with any cutback applied pro rata to all Holders and with each Holder entitled to elect
the portion of its Series B Warrant Shares that are to be cut back; provided, however, that any such Subsequent
Registrable Securities shall cease to be Subsequent Registrable Securities (and the Company shall not be required to maintain
the effectiveness of any, or file another, Registration Statement hereunder with respect thereto other than as set forth below)
as soon as (a) a Registration Statement with respect to the sale of all Subsequent Registrable Securities is declared effective
by the Commission under the Securities Act and all such Subsequent Registrable Securities have been disposed of by the Holders
in accordance with such effective Registration Statement, (b) such Subsequent Registrable Securities have been previously sold
in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions pursuant
to Rule 144 and without the requirement to satisfy the current public information requirements of to Rule 144(c)(1). For the avoidance
of doubt, the fact that Subsequent Registrable Securities may at times cease to be Subsequent Registrable Securities does not
prevent them from again becoming Subsequent Registrable Securities in the future.

 

“Subsequent
Registration Statement” means the Registration Statement filed pursuant to this Agreement covering the Subsequent Registrable
Securities.

 

2.           
Shelf
Registration. On or prior to the applicable Filing Date, the Company shall prepare and file with the Commission an Initial
Registration Statement covering the resale of all Initial Registrable Securities (determined without regard to clause (II) thereof)
on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. On or prior to the
applicable Filing Date, the Company shall prepare and file with the Commission a Subsequent Registration Statement covering the
resale of all Subsequent Registrable Securities (determined without regard to clause (II) thereof) on an effective Registration
Statement for an offering to be made on a continuous basis pursuant to Rule 415. Any Holder that becomes an Affiliate of the Company
may at any time and from time to time request in writing (the date of such request, the “Demand Date”) that
the Company prepare and file on or prior to the applicable Filing Date with the Commission a Demand Registration Statement covering
the resale of all Demand Registrable Securities (determined without regard to clause (II) thereof) on an effective Registration
Statement for an offering to be made on a continuous basis pursuant to Rule 415. On or prior to the applicable Filing Date, the
Company shall prepare and file with the Commission one or more Additional Registration Statement(s) covering the resale of all
Registrable Securities not included in all Registration Statements previously declared effective as a result of a limitation on
the maximum number of shares of Common Stock of the Company permitted to be registered by the staff of the Commission pursuant
to Rule 415, on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each
Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale
the Registrable Securities on Form S-3, in which case such registration shall be on Form S-1 or on another appropriate form in
accordance

    	5

    	 

    
 

herewith
and the Company shall undertake to register the Registrable Securities on Form S-3 as soon as such form is available, provided
that the Company shall use reasonable best efforts to maintain the effectiveness of the Registration Statement then in effect
until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the
Commission). Each Registration Statement shall contain (unless otherwise directed by Holders of at least a majority of Registrable
Securities) substantially the “Plan of Distribution” attached hereto as Annex A, with which each Holder
agrees to comply when selling Registrable Securities pursuant to a Registration Statement. Subject to the terms of this Agreement,
the Company shall use its reasonable best efforts to cause a Registration Statement filed hereunder to be declared effective under
the Securities Act as promptly as possible after the filing thereof, but in any event prior to the applicable Effectiveness Date,
and shall use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act
until all Registrable Securities covered by such Registration Statement (i) have been sold thereunder or pursuant to Rule 144,
or (ii) (A) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and (B) may be sold without the requirement
for the Company to be in compliance with the current public information requirement under Rule 144(c)(1) (the “Effectiveness
Period”). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. New York
City time on a Trading Day. The Company shall promptly notify the Holders via facsimile or by e-mail of the effectiveness of a
Registration Statement on the same Trading Day that the Company confirms effectiveness with the Commission, which shall be the
date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. New York City time on the Trading
Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424.

 

3.           
Registration Procedures.

 

In
connection with the Company’s registration obligations hereunder, the Company shall:

 

(a)               Not
less than three (3) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior
to the filing of any related Prospectus or any amendment or supplement thereto, the Company shall (i) furnish to each Holder copies
of all such documents proposed to be filed (and, promptly upon request of such Holder, copies of documents to be incorporated
or deemed to be incorporated by reference therein), and (ii) cause its officers and directors, counsel and independent registered
public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each
Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not (i) file a Registration
Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable
Securities shall reasonably object in good faith and (ii) submit a request for acceleration of the effectiveness of a Registration
Statement or any amendment or supplement thereto without the

 

    	6

    	 

    
 

prior
approval of Holders of a majority of Registrable Securities, which consent shall not be unreasonably withheld or delayed, provided
that, the Company is notified of such objection in writing no later than five (5) Trading Days after the Holders have been
so furnished copies of a Registration Statement or two (2) Trading Days after the Holders have been so furnished copies of any
related Prospectus or amendments or supplements thereto. As a condition to having the Holder’s Registration Securities included
in a Registration Statement, each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this
Agreement as Annex B (a “Selling Stockholder Questionnaire”) on a date that is the earlier of two (2)
Trading Days prior to the Filing Date or the second (2nd) Trading Day following the date on which such Holder receives draft materials
in accordance with this Section. 

 

(b)           
(i)
Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the
applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such other Registration
Statements, if necessary, in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause
the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement),
and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any
comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly
as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a
Registration Statement (provided that, the Company shall excise any information contained therein which would constitute
material non-public information), and (iv) comply in all material respects with the applicable provisions of the Securities Act
and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during
the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders
thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented. In the case of amendments
and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this
Section 3(b)) by reason of the Company filing a report on Form 10-Q, Form 10-K or any analogous report under the Exchange Act,
the Company shall have incorporated such report by reference into such Registration Statement, if applicable, or shall file such
amendments or supplements with the Commission on the same day on which the Exchange Act report is filed which created the requirement
for the Company to amend or supplement such Registration Statement.

 

    	7

    	 

    
 

(c)           
Notify
the Holders of Registrable Securities to be sold as promptly as reasonably possible (and, in the case of (i)(A) below, not less
than one (1) Trading Day prior to such filing) (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment
to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a “review”
of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect
to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission
or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or
for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any
stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation
of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of
the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation
or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial
statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement
or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or
that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration
Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect
to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best
interest of the Company to allow continued availability of a Registration Statement or Prospectus, provided that,
any and all of such information shall remain confidential to each Holder until such information otherwise becomes public, unless
disclosure by a Holder is required by law or judicial process; provided, further, that notwithstanding each Holder’s
agreement to keep such information confidential, the Company and each such Holder makes no acknowledgement that any such information
is material, non-public information.

 

(d)           
Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending
the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of
any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(e)           
Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto,
including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to
the extent requested by such Person, and all

 

    	8

    	 

    
 

exhibits
to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the
filing of such documents with the Commission; provided, that any such item which is available on the EDGAR system
(or successor thereto) need not be furnished.

 

(f)           
Subject
to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto
by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus
and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(c)(iii) through (vi).

 

(g)           
The
Company shall cooperate with any broker-dealer through which a Holder proposes to resell its Registrable Securities in effecting
a filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by any such Holder.

 

(h)           
Prior to any resale of Registrable Securities by a Holder, use its reasonable best efforts to cooperate with the selling Holders
in connection with the registration or qualification (or exemption from the Registration or qualification) of such Registrable
Securities for the resale by the Holder under the securities or Blue Sky laws of all applicable jurisdictions within the United
States, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do
any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities
covered by each Registration Statement; provided, that, the Company shall not be required to qualify generally to
do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.

 

(i)           
If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free,
to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be
in such denominations and registered in such names as any such Holder may request.

 

(j)           
Upon the occurrence of any event contemplated by Section 3(c)(iii) through (vi), as promptly as reasonably possible under the
circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and its
stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment,
to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated
therein by reference,

 

    	9

    	 

    
 

and
file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading. If the
Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(c) above to suspend the use of any Prospectus
until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company
will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable and
shall notify the Holders in writing of the date on which the Grace Period ends. The Company shall be entitled to exercise its
right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus for a period or periods (each,
a “Grace Period”) not to exceed forty-five (45) calendar days (which need not be consecutive days) in any 12-month
period and any such Grace Period shall not exceed an aggregate of twenty (20) consecutive days and the first day of any
such period must be at least five (5) days after the last day of any such prior Grace Period.
For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Holders
receive the notice referred to in Section 3(c)(iii) through (vi) and shall end on and include the later of the date the Holders
receive the notice referred to in this Section 3(j) and the date referred to in such notice. Notwithstanding anything to the contrary,
the Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of a Holder in accordance
with the terms of the Securities Purchase Agreement in connection with any sale of Registrable Securities with respect to which
a Holder has entered into a contract for sale, prior to the Holder’s receipt of the notice of a Grace Period and for which
the Holder has not yet settled. 

 

(k)           
Comply with all applicable rules and regulations of the Commission.

 

(l)           

The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common
Stock and other securities beneficially owned by such Holder and the natural persons thereof that have voting and dispositive
control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration
of the Registrable Securities solely because any Holder fails to furnish such information within two (2) Trading Days of the Company’s
request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled until such information is
delivered to the Company.

 

(m)           
If (i) the Initial Registration Statement when declared effective fails to register all of the Initial Registrable Securities
(subject to the maximum number of shares of Common Stock of the Company permitted to be registered by the staff of the Commission
pursuant to Rule 415), (ii) a Registration Statement covering all of the Registrable Securities (determined without regard to
clause (II)

 

    	10

    	 

    
 

of the definition of Initial Registrable Securities or Subsequent Registrable Securities) required to be covered thereby
and required to be filed by the Company pursuant to this Agreement is (A) not filed with the Commission on or before the applicable
Filing Date (a “Filing Failure”) or (B) not declared effective by the Commission on or before the applicable
Effectiveness Date (subject to the maximum number of shares of Common Stock of the Company permitted to be registered by the staff
of the Commission pursuant to Rule 415), (an “Effectiveness Failure”) or (iii) on any day after the date a
Registration Statement has been declared effective sales of all of the Registrable Securities required to be included on such
Registration Statement cannot be made (other than during a Grace Period pursuant to such Registration Statement or otherwise)
(including, without limitation, because of the suspension of trading or any other limitation imposed by the Trading Market, a
failure to keep such Registration Statement effective, a failure to disclose such information as is necessary for sales to be
made pursuant to such Registration Statement, a failure to register a sufficient number of shares of Common Stock or a failure
to maintain the listing of the Common Stock) (a “Maintenance Failure”) then, as partial relief for the damages
to any Holder by reason of any such delay in or reduction of its ability to sell the underlying shares of Common Stock (which
remedy shall not be exclusive of any other remedies available at law or in equity, including, without limitation, specific performance),
(A) the Company shall pay to each holder of Registrable Securities relating to such Registration Statement an amount in cash equal
to one percent (1.0%) of the aggregate purchase price paid by such Holders pursuant to the terms of the Securities Purchase Agreement
of such Holder’s Registrable Securities required to be included in such Registration Statement on each of the following
dates: (i) the day of a Filing Failure; (ii) the day of an Effectiveness Failure; (iii) the initial day of a Maintenance Failure;
(iv) on the thirtieth (30th) day after the date of a Filing Failure and every thirtieth (30th) day thereafter (pro rated for periods
totaling less than thirty (30) days) until such Filing Failure is cured; (v) on the thirtieth (30th) day after the date of an
Effectiveness Failure and every thirtieth (30th) day thereafter (pro rated for periods totaling less than thirty (30) days) until
such Effectiveness Failure is cured; and (vi) on the thirtieth (30th) day after the date of a Maintenance Failure and every thirtieth
(30th) day thereafter (pro rated for periods totaling less than thirty (30) days) until such Maintenance Failure is cured. The
payments to which a holder shall be entitled pursuant to this Section 3(m) are referred to herein as “Registration Delay
Payments.” Registration Delay Payments shall be paid on the earlier of (I) the dates set forth above and (II) the third
(3rd) Business Day after the event or failure giving rise to the Registration Delay Payments is cured. In the event the Company
fails to make Registration Delay Payments in a timely manner, such Registration Delay Payments shall bear interest at the rate
of one and one-half percent (1.5%) per month (prorated for partial months) until paid in full.

 

    	11

    	 

    
 

(n)           
The Company shall hold in confidence and not make any disclosure of information concerning a Holder provided to the Company unless
(i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information
is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information
is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction,
or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement
or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning a Holder
is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt written notice to
such Holder and allow such Holder, at the Holder’s expense, to undertake appropriate action to prevent disclosure of, or
to obtain a protective order for, such information.

 

(o)           
If reasonably requested by a Holder, the Company shall as soon as practicable (i) incorporate in a prospectus supplement or post-effective
amendment such information as a Holder reasonably requests to be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold,
the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering;
(ii) make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to
be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration
Statement if reasonably requested by a Holder holding any Registrable Securities.

 

(p)           
The Company shall use its reasonable best efforts to cause the Registrable Securities covered by a Registration Statement to be
registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition
of such Registrable Securities.

 

(q)           
The Company shall make generally available to its security holders as soon as practical, but not later than ninety (90) days after
the close of the period covered by the earning statement referenced immediately hereafter, an earnings statement (in form complying
with, and in the manner provided by, the provisions of Rule 158 under the Securities Act) covering a twelve-month period beginning
not later than the first day of the Company’s fiscal quarter next following the date the applicable Registration Statement
is declared effective.

 

(r)           
Within two (2) Business Days after a Registration Statement which covers Registrable Securities is ordered effective by the Commission,
the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable
Securities (with copies to the Holders whose Registrable Securities are included in such Registration Statement) confirmation
in writing that such Registration Statement has been declared effective by the Commission.

 

    	12

    	 

    
 

(s)           
Neither the Company nor any Subsidiary or Affiliate thereof shall identify any Holder as an underwriter in any public disclosure
or filing with the Commission or any Trading Market and any Holder being deemed an underwriter by the Commission shall not relieve
the Company of any obligations it has under this Agreement or any other Transaction Document; provided,
however, that the foregoing shall not prohibit the Company from including the disclosure
found in the “Plan of Distribution” section attached hereto as Annex A in the Registration Statement.

 

(t)           
The Company shall not file any other registration statements until, or grant registration rights to any Person that can be exercised
prior to, the date that is the later to occur of (I) the date (i) all Shares, (ii) all shares of Common Stock issuable upon exercise
of the Series A Warrants (without regard to any limitations on exercise of the Series A Warrants) and (iii) all shares of Common
Stock issuable upon exercise of any outstanding Series B Warrants (without regard to any limitations on exercise of the Series
B Warrants) either are registered pursuant to a Registration Statement that is declared effective and is effective by the Commission
or may be sold without any restriction or limitation pursuant to Rule 144 and without the requirement to be in compliance with
Rule 144(c)(1) and (II) the Authorized Shares Increase Date (as defined in the Series B Warrants) or the date that no Series B
Warrants are outstanding, provided that this Section 3(t) shall not prohibit the Company from filing amendments (pre-effective
and post-effective) to registration statements filed prior to the date of this Agreement; provided that no such amendment shall
increase the number of securities registered on a registration statement. Notwithstanding the provisions of this Section 3(t)
to the contrary, the Company shall be permitted to file a registration statement registering up to 350,000 shares of Common Stock
(as adjusted for any stock split, stock dividend, stock combination, reclassification or other
similar transaction after the Subscription Date) issuable upon exercise of those certain warrants issued to Noble International
Investments, Inc. on November 9, 2011 and to Chardan Capital Markets, LLC on January 24, 2012 (collectively, the “Financial
Advisors Shares”).

 

(u)           

In no event shall the Company include any securities other than Registrable Securities and the Financial Advisors Shares on any
Registration Statement without the prior written consent of Holders of a majority of Registrable Securities; provided,
however, that in the event the Commission requires the number of shares of Common Stock included in any Registration Statement
to be cut back because of Rule 415 or otherwise, before any Registrable Securities are excluded, the
Financial Advisors Shares shall be first excluded on a pro rata basis until all of the Financial Advisors Shares have been excluded.

 

4.           
Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the
Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement.
The fees and expenses referred to in the foregoing sentence shall include, without

 

    	13

    	 

    
 

limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses of the Company’s counsel and independent registered public accountants)
(A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market
on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws
reasonably agreed to by the Company in writing, (ii) printing expenses (including, without limitation, expenses of printing certificates
for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the
Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other
Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition,
the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions
contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing
of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for
any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal
fees or other costs of the Holders.

 

5.           
Indemnification.

 

(a)           
Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold
harmless each Holder, the officers, directors, members, partners, agents, brokers, representatives, investment advisors and employees
(and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title
or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and
any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or
any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and
all losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs (including, without limitation, reasonable
attorneys’ fees) and expenses, amounts paid in settlement or expenses (collectively, “Losses”), as incurred,
arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement,
any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus or in any
final prospectus or in any filing made in connection with the qualification of the offering under the securities or other “blue
sky” laws of any jurisdiction in which Registrable Securities are offered, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case
of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation

 

    	14

    	 

    
 

or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation
thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the
extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing
to the Company by such Holder expressly for use therein, or (ii) in the case of an occurrence of an event of the type specified
in Section 3(c)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company
has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder
and prior to the receipt by such Holder of the Advice contemplated in Section 7(c). The Company shall notify the Holders promptly
of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by
this Agreement of which the Company is aware.

 

(b)           
Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its
directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the
fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely
upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in
any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein not misleading (i) to the
extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing
by such Holder to the Company specifically for inclusion in such Registration Statement or such Prospectus or (ii) in the case
of an occurrence of an event of the type specified in Section 3(c)(iii)-(vi), the use by such Holder of an outdated, defective
or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective
or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section
7(c). In no event shall the liability of any selling Holder under this Section 5(b) be greater in amount than the dollar amount
of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)           
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume
the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all
fees and expenses incurred in connection with defense thereof;

 

    	15

    	 

    
 

provided, that, the failure of any Indemnified Party
to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except
(and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not
subject to appeal or further review) that such failure shall have prejudiced the Indemnifying Party.

 

An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if
the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party
notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more
than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any
settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed.
No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending
Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such
Indemnified Party from all liability on claims that are the subject matter of such Proceeding and such settlement shall not include
an admission as to fault on the part of the Indemnified Party.

 

Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses
to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with
this Section) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the
Indemnifying Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that
portion of such fees and expenses applicable to such actions for which such Indemnified Party is judicially determined not to
be entitled to indemnification hereunder.

 

Such
indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party
and shall survive the transfer of the Registrable Securities by the Holder pursuant to Section 7(o).

 

    	16

    	 

    
 

(d)           
Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient
to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable
by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified
Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among
other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission
or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by
such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if
the indemnification provided for in this Section was available to such party in accordance with its terms. No Person involved
in the sale of Registrable Securities, which Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) in connection with such sale, shall be entitled to contribution from any Person involved in such sale of
Registrable Securities who was not guilty of fraudulent misrepresentation.

 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by
pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to
contribute pursuant to this Section 5(d), in the aggregate, any amount in excess of the amount by which the net proceeds actually
received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages
that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission.

 

The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties.

 

6.           
Reports
Under the 1934 Act.

 

With
a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act or any other similar rule
or regulation of the Commission that may at any time permit the Holders to sell securities of the Company to the public without
registration (“Rule 144”), the Company agrees to:

 

    	17

    	 

    
 

(a)           
make
and keep public information available, as those terms are understood and defined in Rule 144;

 

(b)           
file
with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is
required for the applicable provisions of Rule 144; and

 

(c)           
furnish
to each Holder so long as such Holder owns Registrable Securities, promptly upon request, (i) a written statement by the Company,
if true, that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, (ii) a copy
of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and
(iii) such other information as may be reasonably requested to permit the Holders to sell such securities pursuant to Rule 144
without registration.

 

7.           
Miscellaneous.

 

(a)           
Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under
this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each
of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by
reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action
for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would
be adequate. The Company therefore agrees that the Holders shall be entitled to seek temporary and permanent injunctive relief
in any such case without the necessity of proving actual damages and without posting a bond or other security.

 

(b)           
Compliance.
Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable
to it, unless exempted therefrom, in connection with sales of Registrable Securities pursuant to a Registration Statement.

 

(c)           
Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice
from the Company of the occurrence of any event of the kind described in Section 3(c)(iii) through (vi), such Holder will forthwith
discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”)
by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company
will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. 

 

    	18

    	 

    
 

(d)           
 Piggy-Back Registrations. Without prejudice to the rights of and obligations to the Holders under Section 3(t), if, at
any time when any Registrable Securities are outstanding, there is not an effective Registration Statement covering all of the
Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating
to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than
on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities
to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with
the Company’s stock option or other employee benefit plans, then the Company shall deliver to each Holder a written notice
of such determination and, if within five (5) Trading Days after the date of the delivery of such notice, any such Holder shall
so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities
such Holder requests to be registered; provided, however, that the Company shall not be required to register any
Registrable Securities pursuant to this Section 7(d) that are eligible for resale pursuant to Rule 144 promulgated by the Commission
pursuant to the Securities Act without any restriction or limitation and without the requirement to be in compliance with Rule
144(c)(1) or that are the subject of a then effective Registration Statement.

 

(e)           
 Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and the Holders of a majority or more of the then outstanding Registrable Securities (including,
for this purpose any Registrable Securities issuable upon exercise or conversion of any Security). If a Registration Statement
does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence,
then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each
Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement.
Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates
exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders
may be given by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided,
however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the
provisions of the first sentence of this Section 7(e). 

 

(f)           
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be delivered as set forth in the Purchase Agreement. 

 

(g)           
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger or

 

    	19

    	 

    
 

otherwise
by operation by law) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding
Registrable Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted
under Section 7(o).

 

(h)           
No Inconsistent Agreements. The Company has not entered, as of the date hereof, nor shall the Company, on or after the
date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights
granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Except as disclosed in the SEC Reports
or in any exhibit thereto, the Company has not previously entered into any agreement granting any registration rights with respect
to any of its securities to any Person that have not been satisfied in full.

 

(i)           
Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

(j)           
Governing Law. All questions concerning the governing law, construction, validity, enforcement and interpretation of this
Agreement and the courts having jurisdiction over, and the proper venue for, the adjudication of any dispute hereunder, shall
be determined in accordance with the provisions of the Purchase Agreement.

 

(k)           
Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.

 

(l)            
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the provision that would otherwise be prohibited, invalid or unenforceable shall
be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability
of such provision shall not affect the validity of the remainder of the terms, provisions, covenants and restrictions set forth
herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as this Agreement
as so modified continues to express, without material change, the original intentions of the parties as to the subject matter
hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise
be conferred upon the parties. The parties hereto shall use their reasonable best efforts to find and employ an alternative means
to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.

 

    	20

    	 

    
 

(m)           
Headings.
The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to
limit or affect any of the provisions hereof.

 

(n)           
 Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not
joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of
the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any
closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Holders are in any way acting in
concert with respect to such obligations or the transactions contemplated by this Agreement. Each Holder shall be entitled to
protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary
for any other Holder to be joined as an additional party in any proceeding for such purpose.

 

(o)            
Assignment of Registration Rights. The rights under this Agreement shall be automatically assignable by the Holders to
any transferee of all or any portion of such Holder’s Registrable Securities if: (i) the Holder agrees in writing with the
transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time
after such assignment; (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written
notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such registration
rights are being transferred or assigned; (iii) immediately following such transfer or assignment the further disposition of such
securities by the transferee or assignee is restricted under the Securities Act or applicable state securities laws; (iv) at or
before the time the Company receives the written notice contemplated by clause (ii) of this sentence the transferee or assignee
agrees in writing with the Company to be bound by all of the provisions contained herein; and (v) such transfer shall have been
made in accordance with the applicable requirements of the Securities Purchase Agreement.

 

********************

  

(Signature
Pages Follow)

 

    	21

    	 

    
 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

 PALATIN
                                                                       TECHNOLOGIES, INC.

 

	 	 	/s/ Stephen T. Wills
	 	By	
	 	 	Name: Stephen T. Wills
	 	 	Title: Executive Vice President, Chief Financial Officer and Chief
    Operating Officer

 

[SIGNATURE
PAGE OF HOLDERS FOLLOWS]

 

    	22

    	 

    

 

[SIGNATURE
PAGE OF HOLDERS TO PTN RRA]

 

 

Name of
Holder: QUINTESSENCE FUND L.P., by its general partner QVT Associates GP LLC

 

Signature
of Authorized Signatory of Holder: ___/s/ Tracy Fu_______________

 

Name of
Authorized Signatory: ______Tracy Fu____________

 

Title of
Authorized Signatory: _______Managing Member ____

 

[SIGNATURE
PAGES CONTINUE]

 

    	23

    	 

    
 

[SIGNATURE
PAGE OF HOLDERS TO PTN RRA]

 

Name of
Holder: QVT FUND IV LP, by its general partner QVT Associates GP LLC

 

Signature
of Authorized Signatory of Holder: ___/s/ Tracy Fu_______________

 

Name of
Authorized Signatory: ______Tracy Fu____________

 

Title of
Authorized Signatory: _______Managing Member ____

 

[SIGNATURE
PAGES CONTINUE]

 

    	24

    	 

    
 

[SIGNATURE
PAGE OF HOLDERS TO PTN RRA]

 

Name of
Holder: QVT FUND V LP, by its general partner QVT Associates GP LLC

 

Signature
of Authorized Signatory of Holder: ___/s/ Tracy Fu_______________

 

Name of
Authorized Signatory: ______Tracy Fu____________

 

Title of
Authorized Signatory: _______Managing Member ____

 

[SIGNATURE
PAGES CONTINUE]

 

    	25

    	 

    
 

Annex
A

 

Plan
of Distribution

 

Each
Selling Stockholder (the “Selling Stockholders”) of the common stock and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of their shares of common stock covered hereby on the principal
Trading Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions
from time to time directly or through one or more underwriters, broker-dealers or agents. These sales may be in one or more transactions
at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or negotiated
prices. A Selling Stockholder may use any one or more of the following methods when selling shares:

 

		•	on
                                                                                                           any national securities
                                                                                                           exchange or quotation
                                                                                                           service on which the
                                                                                                           securities may be listed
                                                                                                           or quoted at the time
                                                                                                           of sale;
		•	in
                                                                                                           the over-the-counter
                                                                                                           market;
		•·	in
                                                                                                           transactions otherwise
                                                                                                           than on these exchanges
                                                                                                           or systems or in the
                                                                                                           over-the-counter market;
		•	ordinary
                                                                                                           brokerage transactions
                                                                                                           and transactions in
                                                                                                           which the broker-dealer
                                                                                                           solicits purchasers;
		•	block
                                                                                                           trades in which the
                                                                                                           broker-dealer will
                                                                                                           attempt to sell the
                                                                                                           shares as agent but
                                                                                                           may position and resell
                                                                                                           a portion of the block
                                                                                                           as principal to facilitate
                                                                                                           the transaction;
		•	purchases
                                                                                                           by a broker-dealer
                                                                                                           as principal and resale
                                                                                                           by the broker-dealer
                                                                                                           for its account;

		•	an
                                                                                                           exchange distribution
                                                                                                           in accordance with
                                                                                                           the rules of the applicable
                                                                                                           exchange;
		•	privately
                                                                                                           negotiated transactions;
		•	short
                                                                                                           sales; 
		•	in
                                                                                                           transactions through
                                                                                                           broker-dealers that
                                                                                                           agree with the Selling
                                                                                                           Stockholders to sell
                                                                                                           a specified number
                                                                                                           of such shares at a
                                                                                                           stipulated price per
                                                                                                           share;
		•	through
                                                                                                           the writing or settlement
                                                                                                           of options or other
                                                                                                           hedging transactions,
                                                                                                           whether through an
                                                                                                           options exchange or
                                                                                                           otherwise;
		•	a
                                                                                                           combination of any
                                                                                                           such methods of sale;
                                                                                                           or
		•	any
                                                                                                           other method permitted
                                                                                                           pursuant to applicable
                                                                                                           law.

 

The
Selling Stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended (the “Securities
Act”), if available, rather than under this prospectus.

Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from
the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal
transaction a markup or markdown in compliance with FINRA IM-2440.

 

In
connection with the sale of the common stock or interests therein, the Selling Stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course
of hedging the positions they assume. The Selling Stockholders may also sell shares of the common stock short and deliver these
securities to close out their short positions and to return borrowed shares in connection with such short sales, or loan or pledge
the common stock to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require
the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

 

The
Selling Stockholders may pledge or grant a security interest in some or all of the warrants or shares
of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured
parties may offer and sell the shares of common stock from time to time pursuant to this prospectus or any amendment to this prospectus
under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended, amending, if necessary, the list
of Selling Stockholder to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus.
The Selling Stockholders also may transfer and donate the shares of common stock in other circumstances in which case the transferees,
donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

 

The
Selling Stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the Common Stock. In no event shall any broker-dealer
receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).

 

    	26

    	 

    
 

The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the shares. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.

 

The
Selling Stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed
sale of the resale shares by the Selling Stockholders.

 

We
agreed to keep this prospectus effective until the earlier of (i) the date on which the shares may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement
for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule
of similar effect or (ii) all of the shares have been sold pursuant to this prospectus or Rule 144 under the Securities Act or
any other rule of similar effect. The resale shares will be sold only through registered or licensed brokers or dealers if required
under applicable state securities laws. In addition, in certain states, the resale shares of Common Stock covered hereby may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or
qualification requirement is available and is complied with.

 

Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale shares may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation
M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions
of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases
and sales of shares of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus
available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser
at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). 

 

Once
sold under the registration statement, of which this prospectus forms a part, the shares of common stock will be freely tradable
in the hands of persons other than our affiliates.

 

    	27

    	 

    
 

Annex
B

 

PALATIN TECHNOLOGIES, INC.

 

Selling
Stockholder Notice and Questionnaire

 

The
undersigned beneficial owner of common stock (the “Registrable Securities”) of Palatin Technologies, Inc.,
a Delaware corporation (the “Company”), understands that the Company has filed or intends to file with the
Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration
Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities
Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration
Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is available from
the Company upon request. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration
Rights Agreement.

Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the
consequences of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The
undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include
the Registrable Securities owned by it in the Registration Statement.

 

    	28

    	 

    
 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

	1.	Name.	 
	 	 	 
	 	(a)	Full
Legal Name of Selling Stockholder
	 	 	 
	 	 	 
	 	 	 
	 	(b)	Full
Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
	 	 	 
	 	 	 
	 	 	 
	 	(c)	Full
Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to
vote or dispose of the securities covered by this Questionnaire):
	 	 	 
	 	 	 

 2.
Address for Notices to Selling Stockholder:

 

	_______________________________________________________________________________________________
	_______________________________________________________________________________________________ 
	_______________________________________________________________________________________________
	Telephone:_____________________________________________________________________________________
	Fax: __________________________________________________________________________________________
	Contact
Person: _________________________________________________________________________________

 

3.
Broker-Dealer Status:

 

 

		(a)	Are you a broker-dealer?
	 	 	 
	 	 	Yes  £          No  £
	 	 	 
	 	(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?
	 	 	 
	 	 	Yes  £          No  £
	 	 	 
	 	Note:	If “yes” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

    	29

    	 

    
 

	 	(c)	Are you an affiliate of a broker-dealer?
	 	 	 
	 	 	Yes  £          No  £
	 	 	 
	 	(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
	 	 	 
	 	 	Yes  £          No  £
	 	 	 
	 	Note:	If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

 

4.
Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.

 

Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the securities issuable pursuant to the Purchase Agreement.

 

 

	 	(a)	Type and Amount of other securities beneficially owned by
the Selling Stockholder:
	 	 	 
	 	 	 

 

5.
Relationships with the Company:

 

Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the past three years.

 

State any exceptions
                                                      here:

 

 

	 	 
	 	 
	 	 

 

The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur
subsequent to the date hereof at any time until the applicable Registration Statement is declared effective.

 

    	30

    	 

    
 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through
5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements
thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation
or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered
either in person or by its duly authorized agent.

Date: Beneficial
Owner: 

 

 

	Date: 	 	Beneficial Owner:
	 	 	 	 
	 	 	By:	 
	 	 	 	Name:
	 	 	 	Title:

 

34EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE
EMPLOYMENT AGREEMENT (“Agreement”) is dated as of July 2, 2012 (the “Effective Date”)
and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (“Company”),
and Karen K. Daniels (“Executive”).

 

BACKGROUND

 

A.                  Executive is currently employed by the Company as its Vice President of Operations. 

 

B.                  
The Company and Executive desire to formally state the terms and conditions of Executive’s
employment by the Company and to provide Executive with certain benefits upon a qualifying termination of such employment.

 

C.                  
The Company desires to employ Executive in the executive capacity hereinafter stated, and
the Executive desires to be employed by the Company in such capacity for the period and with the terms and conditions set forth
herein.

 

AGREEMENT

 

NOW, THEREFORE,
in consideration of the promises and the covenants set forth in this Agreement and for other valuable consideration, the parties
hereby agree as follows:

 

1.                  
Employment. The Company hereby employs Executive as Vice President of Operations, assigned
with responsibilities to do and perform all services, acts, or things necessary or advisable to manage and conduct the business
of the Company, subject at all times to the policies set by the Board of Directors of the Company (the “Board”),
and to the consent of the Board when required by the terms of this contract. Executive hereby accepts such employment and agrees
to devote such time and energies as appropriate to fulfill all responsibilities to the Company. Executive shall be employed at
will.

 

2.                  
Compensation. In consideration for all services rendered by Executive under this Agreement,
Executive shall receive the compensation described in this Section 2. All such compensation shall be paid subject to appropriate
tax withholding and similar deductions.

 

(a)                  Salary. Executive shall be paid an initial annual salary of $225,000, payable in accordance
with the Company’s normal practices in the payment of salary and wages practices, in equal installments, but not less than
24 increments annually.

 

(b)             Executive
Benefit and Incentive Compensation Plans. During employment hereunder, Executive shall be entitled to receive those benefits
which are routinely made available to executive officers of the Company, including participation in any executive stock ownership
plan, profit sharing plan, incentive compensation or bonus plan, retirement plan, Company-provided life insurance, or similar executive
benefit plans maintained or sponsored by the Company. The Company shall not take any action that would materially diminish the
aggregate value of Executive’s fringe benefits as they exist as of the Effective Date of this Agreement or as the same may
be increased from time to time, except for actions taken with respect to officers or employees generally.

 

    	1

    	 

    

 

(c)             Expense
Reimbursement. The Company shall promptly reimburse Executive for all reasonable expenses necessarily incurred during conduct
of Company business, and for which adequate documentation is presented, but in no event later than December 31 of the year
following the year in which the expense was incurred.

 

(d)             Personal
Time Off. Executive shall be entitled to paid time off in accordance with the Company’s policies applicable to executives.

 

3.             
Termination. Executive’s employment may be terminated as follows, with the following effects:

 

(a)             Death.
Executive’s employment shall terminate immediately upon the Executive’s death, in which event the Company’s
only obligations hereunder shall be to pay all compensation and expense reimbursements owing for services rendered and reasonable
business expenses incurred by the Executive prior to the date of Executive’s death. If Executive’s employment ceases
as a result of death, then all unvested options to purchase Common Stock of the Company held by Executive shall immediately terminate
and become unexercisable and all vested options held by Executive shall remain exercisable until the one year anniversary of the
date of cessation of service.

 

(b)             Disability.
In the event the Executive is disabled from performing Executive’s assigned duties under this agreement due to illness
or injury for a period in excess of sixty (60) consecutive days or a period or periods of more than one hundred and twenty
(120) days in the aggregate in any twelve month period, the Board, in its sole discretion, may terminate Executive’s
employment immediately upon written notice to Executive, in which event the Company’s only obligations hereunder shall be
to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by the
Executive prior to the effective date of termination. If Executive’s employment ceases as a result of disability, then all
unvested options to purchase Common Stock of the Company held by Executive shall immediately terminate and become unexercisable
and all vested options held by Executive shall remain exercisable until the one year anniversary of the date of cessation of service.

 

(c)             For
Cause. The Company may terminate Executive’s employment for Cause immediately upon written notice from the Board to Executive.
For purposes of this Agreement, “Cause” means the occurrence of any one or more of the following: (i) Executive’s
conviction of or plea of nolo contendere to any felony crime involving fraud, dishonesty or moral turpitude under the laws of the
United States or any state thereof; (ii) Executive’s attempted commission of, or participation in, a fraud or act of
dishonesty against the Company; (iii) Executive’s intentional, material violation of any contract or agreement between
the Participant and the Company or of any statutory duty owed to the Company; (iv) Executive’s unauthorized use or disclosure
of the Company’s confidential information or trade secrets; or (v) Executive’s gross misconduct. In the event
Executive’s employment is terminated for Cause, the Company shall have no further obligations to Executive other than to
pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive
prior to the effective date of such termination.

 

    	2

    	 

    
 

(d)             Without
Cause. The Company in its sole discretion may terminate Executive’s employment without Cause (as defined above) or prior
warning immediately upon written notice from the Board to Executive, in which event, the Company shall pay to Executive all compensation
and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to the effective
date of termination, and provided such termination is a “separation from service” as such term is defined in Section 409A(a)(2)(A)(i)
of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable guidance thereunder,
contingent upon Executive’s delivery to the Company of an effective Release and Waiver as provided in Section 3(e) below,
the Company shall also provide the following benefits to Executive: (i) severance consisting of continued payment of Executive’s
base salary at the rate in effect as of the effective date of termination, less standard deductions and withholdings, for a period
of nine (9) months following the effective date of termination, subject to acceleration of such payments into a single lump-sum
cash severance payment in the event a Change in Control (as defined below, provided that the Change in Control is an event described
in Code Section 409A(a)(2)(A)(v)) of the Company has occurred prior to the date of termination (but not more than two years
prior to such termination) or a Change in Control occurs within ninety (90) days after the date of termination of Executive’s
employment, provided that any such acceleration complies with the provisions of Code Section 409A(a)(3); (ii) to the
extent that Executive is eligible to continue medical benefits under COBRA and upon timely election by Executive complying with
COBRA, payment of all premiums required to continue Executive’s medical, dental and vision insurance coverage to the extent
permitted by COBRA for a period of nine (9) months following the date of termination (with Executive being responsible to
pay that amount of the portion of the premiums, if any, that Executive would have been responsible to pay if Executive had remained
an employee during such period) or, if earlier, the date that Executive accepts full time employment with another employer; and
(iii) immediate acceleration of the vesting of all options to purchase the common stock of the Company granted to Executive
prior to the effective date of such termination (the “Options”) such that Executive shall be deemed vested
as to the same number of shares as if Executive had continued to be employed by the Company for a period of nine (9) months
following the effective date of such termination (subject to the additional accelerated vesting provided in Section 4(b) in
the event Executive is terminated by the Company without Cause within 90 days prior to or within 13 months following the effective
date of a Change in Control) and all vested options held by Executive shall remain exercisable until the one year anniversary of
the date of cessation of service. As a condition to receiving the continuing benefits specified in this Section 3(d), to the
maximum extent permitted by applicable law, during the nine (9) month period following the Executive’s termination date,
Executive shall not engage in any employment or business activity that is directly competitive with the Company’s business
activities as of such termination date and Executive shall not induce any employee of the Company to leave the employ of the Company.

 

(e)             Release
and Waiver.  As a condition to receiving the benefits specified in Sections 3(d) and 4(b) of this Agreement, Executive must
deliver to the Company a fully effective waiver and release of claims in the form attached hereto as Exhibit A (the
“Release and Waiver”) within the time frame set forth therein, but in no event later than forty-five

 

    	3

    	 

    

 

(45) days following the Executive’s termination date. The Company may withhold payment of the severance compensation
described in paragraph (d) above until Executive executes and delivers the Release and Waiver.

 

(f)             Voluntary
Termination by Executive. Executive may terminate Executive’s employment hereunder at any time, whether with or without
cause, effective thirty (30) days after delivery of written notice of such termination to the Company, except for Executive’s
Emergency Need. “Emergency Need”, as used in this Section, is defined to be the advent of illness or
related health issues in Executive or Executive’s immediate family which a medical doctor would conclude poses a mortal health
risk to that person. The Company shall have the option, in its sole discretion, to specify an earlier termination date than that
provided by Executive in the written notice. Upon voluntary termination pursuant to this Section, the Company shall have no further
obligations to Executive other than to pay all compensation and expense reimbursements owing for services rendered and reasonable
business expenses incurred by Executive prior to effective date of termination as determined by the Company. If Executive voluntarily
terminates Executive’s employment, then all unvested options to purchase Common Stock of the Company held by Executive shall
immediately terminate and become unexercisable and all vested options held by Executive shall remain exercisable for six (6) months
from the date of the voluntary termination.

 

(g)             Resignation
as a Director. In the event of any termination of employment pursuant to this Agreement, Executive shall be deemed to have
resigned voluntarily from the Board and any Committee of the Board, and of the board of directors (and any committee thereof) of
all subsidiaries of the Company, upon the effective date of termination or such earlier date as may be agreed in writing between
the Company and Executive, and Executive’s signature on this Agreement shall, without the need to any further action, constitute
Executive’s resignation from such boards of directors in such circumstance.

 

(h)             Returning
Company Documents. In the event of any termination of Executive’s employment hereunder, Executive shall, prior to or
on such termination deliver to the Company (and will not maintain possession of or deliver to anyone else) any and all devices,
records, data, data bases software, software documentation, laboratory notebooks, notes, reports, proposals, lists, customer lists,
correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions
of any of the above aforementioned items belonging to the Company, its successors or assigns.

 

4.             Change
in Control.

 

(a)             Option
Acceleration Upon a Change in Control. Effective immediately upon the closing of a Change in Control of the Company, the vesting
of all of the then unvested shares of Common Stock subject to the Options shall be accelerated in full and the Options shall become
fully vested and immediately exercisable as to such additional vested shares (and, if any Options have been early exercised by
Executive, the reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such
acceleration shall lapse in full, as appropriate).

 

    	4

    	 

    
 

(b)             Benefits
Upon Termination. In the event that Executive’s employment by the Company is terminated without Cause (as defined above)
or Executive terminates Executive’s employment for Good Reason (as defined below), in each case within ninety (90) days
prior to or within thirteen (13) months following the effective date of a Change in Control (as defined below) of the Company,
contingent upon Executive’s delivery to the Company of a fully effective Release and Waiver as provided in Section 3(e)
and provided such termination is a “separation from service” as such term is defined in Code Section 409A(a)(2)(A)(i),
the Executive shall be entitled to the benefits and payments specified in Sections 3(d)(i) and 3(d)(ii) above, and the vesting
of the unvested shares of Common Stock subject to the Options shall immediately accelerate in full such that the Options shall
become fully vested and exercisable with respect to all of the shares of Common Stock subject to such Options (and, if any Options
have been early exercised by Executive, the reacquisition or repurchase rights held by the Company with respect to the shares
of Common Stock subject to such acceleration shall lapse in full, as appropriate).

 

(c)             Change
in Control. “Change in Control” means the occurrence, in a single transaction or in a series of related
transactions, of any one or more of the following events:

 

(i)             any
Exchange Act Person (as defined below) becomes the beneficial owner, directly or indirectly, of securities of the Company representing
more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by
virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed
to occur (A) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other
Exchange Act Person from the Company in a transaction or series of related transactions the primary purpose of which is to obtain
financing for the Company through the issuance of equity securities or (B) solely because the level of beneficial ownership
held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of
the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing
the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as
a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the
beneficial owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases
the percentage of the then outstanding voting securities beneficially owned by the Subject Person over the designated percentage
threshold, then a Change in Control shall be deemed to occur (for purposes of this Section 4(c), “Exchange Act
Person” means any natural person, entity or “group” (within the meaning of Section 13(d) or 14(d)
of the Securities Exchange Act of 1934, as amended (“Exchange Act”)), except that “Exchange Act
Person” shall not include (A) the Company or any subsidiary of the Company, (B) any employee benefit plan of the
Company or any subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of
the Company or any subsidiary of the Company, (C) an underwriter temporarily holding securities pursuant to an offering of
such securities, (D) an entity beneficially owned, directly or indirectly, by the stockholders of the Company in substantially
the same proportions as their beneficial ownership of stock of the Company; or (E) any natural person, entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the date of this Agreement, is the beneficial
owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting
power of the Company’s then outstanding securities);

    	5

    	 

    
 

(ii)             there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after
the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto
do not beneficially own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent
(50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction
or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in
such merger, consolidation or similar transaction, in each case in substantially the same proportions relative to each other as
their beneficial ownership of the outstanding voting securities of the Company immediately prior to such transaction;

 

(iii)             the
stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete
dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation;

 

(iv)             there
is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of
the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated
assets of the Company and its subsidiaries to an entity, more than fifty percent (50%) of the combined voting power of the
voting securities of which are beneficially owned by stockholders of the Company in substantially the same proportions relative
to each other as their beneficial ownership of the outstanding voting securities of the Company immediately prior to such sale,
lease, license or other disposition; or

 

(v)             individuals
who, on the date of this Agreement, are members of the Board (the “Incumbent Board”) cease for any reason
to constitute at least a majority of the members of the Board; (provided, however, that if the appointment or election (or
nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent
Board then still in office, such new member shall, for purposes of the Plan, be considered as a member of the Incumbent Board).

 

(d)             Good
Reason. “Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean
the occurrence of any of the following events without the Executive’s consent:

 

(i)             a
material adverse change in the nature of the Executive’s authority, duties or responsibilities, as they exist on the Effective
Date of this Agreement;

 

(ii)             
(ii)the relocation of the Company’s executive offices or principal business location to a point more than sixty
(60) miles from their location as of the Effective Date of this Agreement; or

 

(iii)             a
material reduction by the Company of the Executive’s base salary as initially set forth herein or as the same may be increased
from time to time, except for

 

    	6

    	 

    
 

across-the-board salary reductions based on the Company’s financial performance similarly affecting
all or substantially all senior officers of the Company and does not exceed 15% of Executive’s base salary.

 

Provided however that,
such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if: (i) the Executive
gives the Company written notice of the intent to terminate for Good Reason within thirty (30) days following the first occurrence
of the condition(s) that the Executive believes constitutes Good Reason, which notice shall describe such condition(s); (ii) the
Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure
Period”); and (iii) the Executive terminates employment within thirty (30) days following the end of the
Cure Period.

 

5.             Application
of Internal Revenue Code Section 409A. Benefits payable under the Agreement, to the extent of payments made from the date
of termination of the Executive through March 15th of the calendar year following such termination, are intended to constitute
separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus payable pursuant to the “short-term
deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations; to the extent such payments are made
following said March 15th, they are subject to the distribution requirements of Code Section 409A(a)(2)(A), including,
without limitation, the requirement of Code Section 409A(a)(2)(B)(i) that payment to the Executive be delayed until 6 months
after separation from service if the Executive is a “specified Executive” within the meaning of the aforesaid section
of the Code at the time of such separation from service. In addition, if any provision of this Agreement would cause Executive
to incur any penalty tax or interest under Section 409A of the Code or any regulations or Treasury guidance promulgated thereunder,
the Company may reform such provision to maintain to the maximum extent practicable the original intent of the applicable provision
without violating the provisions of Section 409A of the Code.

 

6.             Code
Section 280G. If any payment or benefit Executive would receive pursuant to a Corporate Transaction from the Company or
otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning
of Code Section 280G, and (ii) but for this sentence, be subject to the excise tax imposed by Code Section 4999
(the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Payment
are paid to Executive, which of the following two amounts would maximize Executive’s after-tax proceeds: (i) payment
in full of the entire amount of the Payment (a “Full Payment”), or (ii) payment of only a part of
the Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced
Payment”), whichever amount results in Executive’s receipt, on an after-tax basis, of the greater amount of
the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. For purposes of determining
whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state
and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum
reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment
is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall
have no rights to any additional payments and/or benefits constituting the Payment, and (ii) reduction in payments and/or
benefits shall occur in the following order: reduction of cash payments, cancellation of accelerated vesting of

 

    	7

    	 

    
 

stock awards, and
reduction of other benefits. In the event that acceleration of compensation from Executive’s equity awards is to be reduced,
such acceleration of vesting shall be canceled in the reverse order of the date of grant unless Executive elects in writing a different
order for cancellation.

 

The independent
registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of
the Corporate Transaction shall make all determinations required to be made under this Section 6. If the independent registered
public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting
the Corporate Transaction, the Company shall appoint a different nationally recognized independent registered public accounting
firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such
independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm
engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to
the Company and Executive within fifteen (15) calendar days after the date on which Executive’s right to a Payment is
triggered (if requested at that time by the Company or Executive) or at such other time as requested by the Company. If the independent
registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the
application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive
that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder
shall be final, binding and conclusive upon the Company and Executive.

 

7.             Conflict
of Interest. During the Employment Period, Executive shall devote such time and energies as appropriate to fulfill all responsibilities
to the Company in the capacity set forth in Section 1. Executive shall be free to pursue business activities which do not
interfere with the performance of Executive’s duties and responsibilities under this Agreement, however, Executive shall
not engage in any outside business activity which involves actual or potential competition with the business of the Company, except
with the written consent of the Board.

 

8.             Executive
Benefit Plans. All of the Executive benefit plans referred to or contemplated by this Agreement shall be governed solely by
the terms of the underlying plan documents and applicable law. Nothing in this Agreement shall impair the Company’s right
to amend, modify, replace, and terminate any and all such plans in its sole discretion as provided by law. This Agreement is for
the sole benefit of Executive and the Company, and is not intended to create an Executive benefit plan or to modify existing terms
of existing plans.

 

9.             Assignment.
This Agreement may not be assigned by Executive. This Agreement shall bind and inure to the benefit of the Company’s
successors and assigns, as well as Executive’s heirs, executors, administrators, and legal representatives. The Company shall
obtain from any successor, before the succession takes place, an agreement to assume the obligations and perform all of the terms
and conditions of this Agreement.

 

10.             Notices.
All notices required by this Agreement may be delivered by first class mail at the following addresses:

    	8

    	 

    
 

To Company:

Adamis Pharmaceuticals Corporation

Attn: Board of Directors

11455 El Camino Real, Suite 310

San Diego, CA 92130

To Executive:

 

Karen K. Daniels

______________

__________, CA 92___

 

11.             Amendment.
This Agreement may be modified only by written agreement signed by both the Company and Executive.

 

12.             Choice
of Law; Arbitration. This Agreement shall be governed by the laws of the State of California, without regard to choice of law
principles. To provide a mechanism for rapid and economical dispute resolution, Executive and the Company agree that any and all
disputes, claims, or causes of action, in law or in equity, arising from or relating to this Agreement (including the Release and
Waiver) and its enforcement, performance, breach or interpretation, will be resolved, to the fullest extent permitted by law, by
final, binding and confidential arbitration before a single arbitrator held in San Diego, California and conducted by the American
Arbitration Association (“AAA”), under its then-existing rules and procedures. The parties shall be entitled
to conduct adequate discovery, and they may obtain all remedies available to the parties as if the matter had been tried in court.
The arbitrator shall issue a written decision which specifies the findings of fact and conclusions of law on which the arbitrator’s
decision is based. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof.
Unless a different allocation is required by law, the parties shall each pay one-half of all fees and costs of the arbitration.
Punitive damages shall not be awarded. Unless otherwise required by law, the arbitrator will award reasonable expenses (including
reimbursement of the assigned arbitration costs) to the prevailing party. Nothing in this Section or in this Agreement is intended
to prevent either Executive or the Company from obtaining injunctive relief in a court of competent jurisdiction to prevent irreparable
harm pending the conclusion of any such arbitration. Notwithstanding the above, both Executive and the Company retain the
right to seek or obtain, and shall not be prohibited, limited or in any other way restricted from seeking or obtaining, equitable
relief from a court having jurisdiction over the parties in order to enforce the nonsolicitation and noncompetition provisions
of this Agreement or any disputes or claims relating to or arising out of the misuse or misappropriation of the Company’s
intellectual property.

 

13.             Partial
Invalidity. In the event any provision of this Agreement is void or unenforceable, the remaining provisions shall continue
in full force and effect.

 

14.             Waiver.
No waiver of any breach of this Agreement shall constitute a waiver of any subsequent breach.

 

    	9

    	 

    
 

15.             Complete
Agreement. As of the Effective Date, this Agreement, together with the stock option agreements and equity incentive plans governing
the Options, constitutes the entire agreement between the parties in connection with the subject matter hereof and supersedes any
and all prior or contemporaneous oral and written agreements or understandings between the parties.

 

16.             Headings.
Headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement
for any other purpose.

 

17.             Miscellaneous.
Executive acknowledges full understanding of the matters set forth herein and the obligations undertaken upon the execution
hereof.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

    	10

    	 

    
 

IN
WITNESS WHEREOF, the parties have executed this EXECUTIVE EMPLOYMENT AGREEMENT as of the date first written above.

 

ADAMIS PHARMACEUTICALS CORPORATION

 

	By: 	/s/ Dennis J. Carlo	 
	Name:	Dennis J. Carlo	 
	Title:	President and CEO	 
	 	 	 
	EXECUTIVE:	 
	 	 	 
	By: 	 /s/ Karen K. Daniels	 
	Name:	Karen K. Daniels	 
	Title:	Vice President of Operations	 

 

    	

    	 

    
 

EXHIBIT A

 

RELEASE AND WAIVER OF CLAIMS

 

In consideration of the severance
payments and other benefits set forth in the Executive Employment Agreement dated as of July 2, 2012 (the “Employment
Agreement”), to which this form is attached, I, Karen K. Daniels, hereby furnish Adamis Pharmaceuticals
Corporation (the “Company”), with the following release and waiver (“Release and Waiver”)
and, intended to be legally bound hereby, agree as follows.

 

In exchange for the consideration
provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release
the Company and its directors, officers, Executives, shareholders, partners, agents, attorneys, predecessors, successors, parent
and subsidiary entities, insurers, Affiliates, and assigns from any and all claims, liabilities and obligations, both known and
unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this
Release and Waiver. This general release includes, but is not limited to: (1) all claims arising out of or in any way related
to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits
from the Company, including, but not limited to, salary, bonuses, commissions, vacation pay, expense reimbursements, severance
pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of
contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including,
but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all
federal, state, and local statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation,
attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with
Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”),
and the California Fair Employment and Housing Act (as amended). Nothing in this Release and Waiver shall be deemed to require
the waiver or release of any claim that may not be released or waived under applicable federal or state law.

 

I also acknowledge that I have read
and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend
to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which
if known by him or her must have materially affected his or her settlement with the debtor.”  I hereby expressly waive
and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to any
claims I may have against the Company.

 

I acknowledge that, among other rights,
I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the
consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive
of the Company. I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that:
(a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and
Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver;

 

    	A-1

    	 

    
 

(c) I have twenty-one
(21) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although
I may choose voluntarily to execute this Release and Waiver earlier); (d) I have seven (7) days following the execution
of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective
until the seven (7) day revocation period has expired unexercised and no benefits will be paid unless and until this Release
and Waiver has become effective. In the event that this Release and Waiver is requested in connection with an exit incentive or
other employment termination program offered to a group or class of employees, I have forty-five (45) days to consider this
Release and Waiver and I shall be provided with the information required by 29 U.S.C. Section 626 (f)(1)(H).

 

In consideration of the severance
payments and other benefits set forth in the Employment Agreement, I agree that after the termination of my employment with the
Company I will not disparage the Company or its products, services, agents, representatives, directors, officers, shareholders,
employees, affiliates, successors or assigns, or any person acting by, through, under or in concert with any of them with any written
or oral statement. I also agree that during the severance period set forth in the Employment Agreement
I will cooperate from time to time with the Company in providing for the orderly transition of my duties and responsibilities to
other individuals, as reasonably requested by the Company and subject to reimbursement by the Company of any costs or expenses
incurred by me in providing such cooperation. 

 

This Release and Waiver constitutes
the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter
hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and
Waiver may only be modified by a writing signed by both me and a duly authorized member of the Board of Directors of the Company.

 

	Date: _______, 20__	 	
	 	 	Karen K. Daniels

 

A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]